Plain-English translation of NCT05899621 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study that tracks how well —a targeted cancer medication—works when combined with other chemotherapy drugs to treat follicular lymphoma in patients who have never received treatment before. Researchers will collect information from your medical records about how you respond to treatment, any side effects you experience, and other details that might help predict how well the medication works for different patients.
Follicular lymphoma is a slow-growing blood cancer, and while several treatment options exist, doctors want to better understand which combinations work best for which patients in real-world settings. This study aims to gather practical information from everyday clinical care to improve treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would continue your regular cancer treatment with your doctor as planned—either with combined with , , or CHOP chemotherapy. The study does not change your treatment; instead, researchers collect your medical data from your clinic visits, lab tests, and imaging scans over time. Your participation involves sharing this information for about 2 years while you receive your induction chemotherapy (6 cycles of about 3 weeks each) and then maintenance treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Sponsor
Ruijin Hospital
Enrollment target
~332 participants
Started
June 2023
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Weili Zhao, +862164370045
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.